JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266011

Human FHL1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

FHL1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Western blot - Human FHL1 knockout HeLa cell line (AB266011)
  • WB

Lab

Western blot - Human FHL1 knockout HeLa cell line (AB266011)

Lanes 1-4 : Merged signal (red and green). Green - ab255828 observed at 32 kDa. Red - loading control ab7291 observed at 50 kDa.

ab255828 Anti-FHL1 antibody [EPR22842-95] was shown to specifically react with FHL1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab266011 (knockout cell lysate ab257952) was used. Wild-type and FHL1 knockout samples were subjected to SDS-PAGE. ab255828 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-FHL1 antibody [EPR22842-95] (<a href='/en-us/products/primary-antibodies/fhl1-antibody-epr22842-95-ab255828'>ab255828</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

FHL1 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human FHL1 knockout HeLa cell line (ab266011)

Lane 3:

HEK293T cell lysate at 20 µg

Lane 4:

Daudi cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 36 kDa

Observed band size: 32 kDa

false

Sanger Sequencing - Human FHL1 knockout HeLa cell line (AB266011)
  • Sanger seq

Unknown

Sanger Sequencing - Human FHL1 knockout HeLa cell line (AB266011)

Allele-1 : 1 bp deletion in exon 4.

Sanger Sequencing - Human FHL1 knockout HeLa cell line (AB266011)
  • Sanger seq

Lab

Sanger Sequencing - Human FHL1 knockout HeLa cell line (AB266011)

Allele-2 : Insertion of the selection cassette in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266011-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266011 Human FHL1 knockout HeLa cell line", "number":"AB266011-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266011-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266011-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266011-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266011 Human FHL1 knockout HeLa cell line", "number":"AB266011-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266011-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266011 Human FHL1 knockout HeLa cell line", "number":"AB266011-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266011-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266011 Human FHL1 knockout HeLa cell line", "number":"AB266011-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
FHL1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The FHL1 protein also known as Four and a Half LIM Domains 1 operates mechanically as a multifunctional adaptor protein. Its molecular mass is approximately 35 kDa. This protein is widely expressed in skeletal muscle and heart tissues playing a role in various cellular contexts. FHL1 interacts within the cell cytoplasm and nucleus allowing it to assist in multiple cellular processes.
Biological function summary

FHL1 integrates into diverse cellular mechanisms by engaging in protein-protein interactions. It acts as part of complexes that regulate transcription cell differentiation and development. The involvement of FHL1 in muscle growth and maintenance is significant partly due to its expression pattern. In skeletal muscles it helps adapt muscle response to mechanical stress while in cardiac tissue it participates in muscle contractility and integrity.

Pathways

FHL1 plays important roles in both the muscle differentiation pathway and the MAPK/ERK signaling pathway. It influences the transcriptional regulation essential for muscle cell growth and differentiation. FHL1 interacts with proteins such as MyoD during muscle formation and MEF2 in the MAPK/ERK pathway modulating cellular responses to external signals and stressors.

FHL1's involvement is evident in conditions such as Emery-Dreifuss muscular dystrophy and cardiomyopathy. Mutations or dysregulation of this protein can impair muscle function leading to myopathy. It associates with other proteins like emerin in genetic disorders affecting muscle tissues and structural integrity revealing its vital role in maintaining muscular health.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com